European Working Party on Systemic Lupus Erythematosus and European Forum on Antiphospholipid Antibodies: two networks promoting European research on autoimmunity

Cervera, Ricard; Tincani, Anǵela

doi:10.1177/0961203309106812

Cited by 11 publications

(5 citation statements)

References 20 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The etiology and pathogenetic mechanisms of SLE are still unclear; no single cause for SLE has been identified (2). It is possible that the autoimmune disorder results from the combination of predisposing genetic factors and the disturbed status of stress response mechanisms, including the sympathetic nervous system and various hormones (3).…”

mentioning

confidence: 99%

Diagnostic utility of serum melatonin levels in systemic lupus erythematosus: a case-control study

2017

View full text Add to dashboard Cite

SUMMARYSystemic lupus erythematosus (SLE) is a chronic systemic autoimmune inflammatory disease and early diagnosis is of clinical and therapeutic importance. Melatonin is an endogenous endolamine hormone that plays an important role in the immune system due to its anti-inflammatory action. This study was designed to assess serum melatonin levels in SLE patients and to evaluate the possible correlation between serum melatonin and patients' baseline characteristics. A case-control study was performed on 50 SLE patients (48 females and 2 males), diagnosed according to the revised 1997 ACR Criteria, and 25 healthy controls (24 females and 1 male), matched by age and sex. Daily serum melatonin levels were investigated in all participants using human melatonin enzyme linked immunosorbent assay (ELISA) kit (MYBIOSOURCE (MBS), United States). Serum melatonin concentration was significantly lower in patients with SLE compared to healthy controls (19.17±6.86 pg/mL vs 23.26±6.71 pg/mL, p=0.017). Serum melatonin concentration ≤18.51 pg/mL was the optimum cut off value to differentiate between SLE patients and healthy controls with an accuracy of 69.3%, a sensitivity of 66%, and a specificity of 76%. The positive predictive value (PPV) at pretest 50% was 73.3% and PPV at pretest 90% was 96.1%; the negative predictive value (NPV) at 10% was 95.3%. Patients' characteristics were not significantly correlated with serum melatonin concentrations using multiple logistic regression analysis. Serum melatonin was a valid measure to differentiate between SLE patients and healthy controls with good accuracy, sensitivity and specificity and PPV and NPV. There was no significant correlation between serum melatonin concentrations and patients' baseline characteristics.Key words: Serum melatonin; systemic lupus erythematosus; autoimmune diseases. Reumatismo, 2017; 69 (4): 170-174 n INTRODUCTION S ystemic lupus erythematosus (SLE) is a multisystem autoimmune disease, characterized by a multitude of autoantibodies, complement activation and immune-complex deposition, which causes tissue and organ damage (1). The etiology and pathogenetic mechanisms of SLE are still unclear; no single cause for SLE has been identified (2). It is possible that the autoimmune disorder results from the combination of predisposing genetic factors and the disturbed status of stress response mechanisms, including the sympathetic nervous system and various hormones (3). Melatonin, produced by the pineal gland during the night, is the major secretory hormone and a key player in the neuroendocrine-immune pathway (4, 5). Melatonin can stimulate cytokine production, phagocytosis and natural killer cell activity. In vitro studies and animal experiments have provided evidence for a modulatory effect of melatonin in the immune response: melatonin receptors are expressed on the membrane of CD4 T cells, CD8 T cells, and B cells (6, 7), and melatonin treatment in mice showed increasing proliferation of T cells (8). In addition, it can antagonize the increasing levels of I...

show abstract

mentioning

confidence: 99%

Diagnostic utility of serum melatonin levels in systemic lupus erythematosus: a case-control study

2017

View full text Add to dashboard Cite

show abstract

“…An aPL-triggered sudden disturbance of the coagulation or fibrinolytic systems is an expected finding. In the light of the rarity of the condition, the European Forum on Antiphospholipid Antibodies established an international list of patients with catastrophic APS (the CAPS Registry) in 2000 7,8 . Catastrophic APS is assessed based on diagnostic criteria, and diagnosis may be definite or probable (Table 2).…”

Section: Casementioning

confidence: 99%

Sjögren sendromu ve şiddetli cilt tutulumu mevcut olan katastrofik antifosfolipid sendromu

Karagün

Öneç

Akbaş

et al. 2020

Cukurova Medical Journal

View full text Add to dashboard Cite

Öz Catastrophic antiphospholipid syndrome is a rare but rapidly progressing form of antiphospholipid antibody syndrome with high mortality. The syndrome causes multiorgan failure associated with diffuse microthromboses. Necrotic-appearing ecchymotic lesions emerging from the distal aspect of both lower extremities and progressing to the upper leg region, and to the upper extremities developed in a 58-year-old woman. Histopathological examination of the biopsy specimen revealed intravascular microthrombi in the dermis. Laboratory findings for anti-cardiolipin antibodies IgM and lupus anticoagulant resulted positive. Lung and kidney involvement was observed. The clinical course progressed very quickly, and catastrophic antiphospholipid syndrome was diagnosed with these findings. Two-thirds of catastrophic antiphospholipid syndrome cases develop due to secondary causes, the most common being infections. Catastrophic antiphospholipid syndrome may also accompany autoimmune diseases, particularly systemic lupus erythematosus. This report is presented to emphasize that Sjögren's syndrome should be considered in the etiology of catastrophic antiphospholipid syndrome.

show abstract

“…Later on, eight successful meetings of the European Forum on aPL were organized in different cities (Paris, Venice, Utrecht, London, Barcelona, Ljubljana, Marseille and Padova) (Table 1) and, nowadays, more than 20 different European countries are represented in this Forum. 1 During the Forum meetings, the collaboration starts with the creation of different projects and internet-based registers. The multicentre projects (or registers) are first presented, discussed and eventually improved with suggestions from different delegates; in addition, projects can be joined by interested groups hearing the presentation.…”

Section: Brief History Of the European Forummentioning

confidence: 99%

Section: Brief History Of the European Forummentioning

confidence: 99%

European Forum On Antiphospholipid Antibodies: brief history report and governance document

Cervera

2012

Lupus

Self Cite

View full text Add to dashboard Cite

The European Forum on Antiphospholipid Antibodies was conceived as a multidisciplinary network of different specialists working in the fields of internal medicine, haematology, rheumatology, obstetrics and gynaecology, neurology, paediatrics, cardiology and immunology, among others, that share a common interest in these antibodies and antiphospholipid syndrome (APS). Centres with very good clinical practice in APS and with large cohorts of patients could join other centres with better research experience, thus allowing the study of basic patho-mechanisms in large series of patients. In addition, the specialists would be able to compare their cohorts of patients, which, being as they are recruited in very different fields of medicine, could enlighten the different aspects of APS. Finally, continuous comparison of patients' data suggested that even the laboratory diagnostic procedures needed collaborative work in order to make reproducible results, at least of the classical tests--lupus anticoagulant (LA), anticardiolipin antibodies (aCLas) and anti β(2)-glycoprotein I antibodies (anti-β(2)GPIs)--and of the consequent clinical diagnosis in different centres. In this way, the wide exchange of information could also favour the introduction and evaluation of new tests.

show abstract

European Working Party on Systemic Lupus Erythematosus and European Forum on Antiphospholipid Antibodies: two networks promoting European research on autoimmunity

Cited by 11 publications

References 20 publications

Diagnostic utility of serum melatonin levels in systemic lupus erythematosus: a case-control study

Diagnostic utility of serum melatonin levels in systemic lupus erythematosus: a case-control study

Sjögren sendromu ve şiddetli cilt tutulumu mevcut olan katastrofik antifosfolipid sendromu

European Forum On Antiphospholipid Antibodies: brief history report and governance document

Contact Info

Product

Resources

About